Alley Investment Management Company LLC Sells 124 Shares of Stryker Corporation $SYK

Alley Investment Management Company LLC cut its stake in Stryker Corporation (NYSE:SYK) by 0.4% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 34,086 shares of the medical technology company’s stock after selling 124 shares during the quarter. Stryker comprises approximately 1.6% of Alley Investment Management Company LLC’s holdings, making the stock its 27th largest holding. Alley Investment Management Company LLC’s holdings in Stryker were worth $13,485,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of the stock. Sunflower Bank N.A. increased its position in shares of Stryker by 4.0% in the second quarter. Sunflower Bank N.A. now owns 696 shares of the medical technology company’s stock valued at $275,000 after buying an additional 27 shares in the last quarter. Pitti Group Wealth Management LLC boosted its stake in shares of Stryker by 3.2% in the second quarter. Pitti Group Wealth Management LLC now owns 861 shares of the medical technology company’s stock worth $341,000 after acquiring an additional 27 shares during the last quarter. Continuum Advisory LLC boosted its stake in shares of Stryker by 5.8% in the first quarter. Continuum Advisory LLC now owns 532 shares of the medical technology company’s stock worth $198,000 after acquiring an additional 29 shares during the last quarter. Oakworth Capital Inc. boosted its stake in shares of Stryker by 0.5% in the first quarter. Oakworth Capital Inc. now owns 6,133 shares of the medical technology company’s stock worth $2,283,000 after acquiring an additional 29 shares during the last quarter. Finally, Strategy Asset Managers LLC boosted its stake in shares of Stryker by 1.4% in the first quarter. Strategy Asset Managers LLC now owns 2,134 shares of the medical technology company’s stock worth $794,000 after acquiring an additional 29 shares during the last quarter. 77.09% of the stock is currently owned by institutional investors.

Stryker Stock Down 0.1%

Shares of NYSE:SYK opened at $369.44 on Wednesday. Stryker Corporation has a 1 year low of $329.16 and a 1 year high of $406.19. The firm has a market capitalization of $141.24 billion, a PE ratio of 48.93, a price-to-earnings-growth ratio of 2.67 and a beta of 0.93. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.78 and a quick ratio of 1.06. The firm’s 50-day moving average is $384.81 and its two-hundred day moving average is $379.11.

Stryker (NYSE:SYK) last announced its quarterly earnings data on Thursday, July 31st. The medical technology company reported $3.13 EPS for the quarter, topping analysts’ consensus estimates of $3.07 by $0.06. Stryker had a return on equity of 23.94% and a net margin of 12.25%.The business had revenue of $6.02 billion during the quarter, compared to the consensus estimate of $5.92 billion. During the same period in the previous year, the company posted $2.81 earnings per share. The business’s revenue for the quarter was up 11.1% on a year-over-year basis. Stryker has set its FY 2025 guidance at 13.400-13.600 EPS. Analysts predict that Stryker Corporation will post 13.47 EPS for the current year.

Stryker Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Tuesday, September 30th will be given a dividend of $0.84 per share. The ex-dividend date of this dividend is Tuesday, September 30th. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.9%. Stryker’s payout ratio is currently 44.50%.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on SYK. BTIG Research reaffirmed a “buy” rating on shares of Stryker in a research note on Monday, July 14th. Rothschild Redb raised Stryker to a “hold” rating in a research note on Thursday, September 18th. Needham & Company LLC lifted their price target on Stryker from $442.00 to $448.00 and gave the stock a “buy” rating in a research note on Friday, August 1st. Truist Financial set a $415.00 price objective on Stryker and gave the stock a “hold” rating in a research note on Monday, August 4th. Finally, Rothschild & Co Redburn began coverage on Stryker in a research note on Thursday, September 18th. They set a “neutral” rating and a $420.00 price objective on the stock. Fourteen investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $430.33.

Insider Transactions at Stryker

In related news, insider Viju Menon sold 500 shares of the company’s stock in a transaction that occurred on Monday, August 25th. The stock was sold at an average price of $390.61, for a total value of $195,305.00. Following the completion of the transaction, the insider directly owned 12,511 shares of the company’s stock, valued at $4,886,921.71. This represents a 3.84% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Ronda E. Stryker sold 200,000 shares of the company’s stock in a transaction that occurred on Wednesday, August 6th. The shares were sold at an average price of $376.45, for a total value of $75,290,000.00. Following the completion of the transaction, the director directly owned 3,222,108 shares of the company’s stock, valued at $1,212,962,556.60. This trade represents a 5.84% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 5.20% of the company’s stock.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.